SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
205 hedge funds and large institutions have $691M invested in SANGAMO THERAPEUTICS INC in 2020 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 76 increasing their positions, 47 reducing their positions, and 15 closing their positions.
107% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 15
62% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 47
47% more call options, than puts
Call options by funds: $15.5M | Put options by funds: $10.5M
45% more capital invested
Capital invested by funds: $476M → $691M (+$215M)
8% more funds holding
Funds holding: 190 → 205 (+15)
9.42% less ownership
Funds ownership: 64.14% → 54.73% (-9.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$15.2M |
| 2 |
Two Sigma Investments
New York
|
+$10.9M |
| 3 |
BlackRock
New York
|
+$8.98M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.78M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$7.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$14.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$10.6M |
| 3 |
Millennium Management
New York
|
-$9.48M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$8.68M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$4.21M |
SGMO Hedge Fund Activity: Q2 2020 in Review
205 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2020, worth a combined $691M — up 45% from $476M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SGMO positions and 15 closed out — a net gain of 16 holders — while 76 added to existing stakes and 47 trimmed.
The largest buyer was State Street, adding an estimated $15.2M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $14.7M sold.
- 205 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2020, up from 190 in Q1 2020.
- Funds reported $691M of SANGAMO THERAPEUTICS INC stock for Q2 2020, up 45% quarter-over-quarter.
- 31 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2020 and 15 closed out, a net change of +16 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q2 2020 was State Street, an estimated $15.2M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q2 2020 was EcoR1 Capital, an estimated $14.7M sold.
Based on aggregated 13F filings for Q2 2020.